ArticleMolecular pharmaceutics2019
Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[
Article in Molecular pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Exclusively ChemoselectiveACS omega · 2026Article
- A novelEJNMMI radiopharmacy and chemistry · 2026Article
- Novel Molecular Classification of Breast Cancer with PET Imaging.Medicina (Kaunas, Lithuania) · 2024Review
- Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years.Journal of nanobiotechnology · 2024Review
- Radiosynthesis, structural identification and in vitro tissue binding study of [EJNMMI radiopharmacy and chemistry · 2024Article
- Radiosynthesis and preclinical evaluations of [American journal of nuclear medicine and molecular imaging · 2024Article
- Small Antibodies with Big Applications: Nanobody-Based Cancer Diagnostics and Therapeutics.Cancers · 2023Review
- Review
- Camels' biological fluids contained nanobodies: promising avenue in cancer therapy.Cancer cell international · 2022Review
- Evaluation of anScientific reports · 2022Article
- Site-Specific and Residualizing Linker forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides.Molecules (Basel, Switzerland) · 2021Review
- Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies.International journal of molecular sciences · 2021Review
- Radiolabeling Strategies of Nanobodies for Imaging Applications.Diagnostics (Basel, Switzerland) · 2021Review
- HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging.European journal of nuclear medicine and molecular imaging · 2021Review
- Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.Nuclear medicine and biology · 2021Article
- Labeling a TCO-functionalized single domain antibody fragment withBioorganic & medicinal chemistry · 2020Article
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics.Frontiers in oncology · 2020Review
- Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided Surgery.Antibodies (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
ImmunoPET agents are being investigated to assess the status of epidermal growth factor receptor 2 (HER2) in breast cancer patients with the goal of selecting those likely to benefit from HER2-targeted therapies and monitoring their progress after these treatments. We have been exploring the use of single domain antibody fragments (sdAbs) labeled with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.